- Home
- TOPS vs TENX Comparison
TOPS vs TENX Comparison
Compare TOPS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- TENX
- Stock Information
- Founded
- TOPS 2000
- TENX 1967
- Country
- TOPS Greece
- TENX United States
- Employees
- TOPS N/A
- TENX N/A
- Industry
- TOPS Marine Transportation
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- TENX Health Care
- Exchange
- TOPS Nasdaq
- TENX Nasdaq
- Market Cap
- TOPS 27.0M
- TENX 27.3M
- IPO Year
- TOPS 2004
- TENX N/A
- Fundamental
- Price
- TOPS N/A
- TENX $7.79
- Analyst Decision
- TOPS
- TENX Strong Buy
- Analyst Count
- TOPS 0
- TENX 4
- Target Price
- TOPS N/A
- TENX $16.67
- AVG Volume (30 Days)
- TOPS 7.6K
- TENX 119.0K
- Earning Date
- TOPS 11-13-2025
- TENX 11-12-2025
- Dividend Yield
- TOPS N/A
- TENX N/A
- EPS Growth
- TOPS N/A
- TENX N/A
- EPS
- TOPS 2.30
- TENX N/A
- Revenue
- TOPS $87,872,000.00
- TENX N/A
- Revenue This Year
- TOPS $9.90
- TENX N/A
- Revenue Next Year
- TOPS N/A
- TENX N/A
- P/E Ratio
- TOPS $2.55
- TENX N/A
- Revenue Growth
- TOPS 3.83
- TENX N/A
- 52 Week Low
- TOPS $5.00
- TENX $3.25
- 52 Week High
- TOPS $11.47
- TENX $7.98
- Technical
- Relative Strength Index (RSI)
- TOPS N/A
- TENX 77.22
- Support Level
- TOPS N/A
- TENX $7.45
- Resistance Level
- TOPS N/A
- TENX $7.82
- Average True Range (ATR)
- TOPS 0.00
- TENX 0.31
- MACD
- TOPS 0.00
- TENX 0.06
- Stochastic Oscillator
- TOPS 0.00
- TENX 84.50
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.